Hepatology
Grazoprevir with elbasvir
Brand: Zepatier
PBAC's latest decision on Grazoprevir with elbasvir: Deferred (2018). Considered for Chronic Hepatitis C Virus infection – Genotype 1 or 4 in adults.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2018 → 2018
Eligible population
Adults with chronic Hepatitis C Virus infection – Genotype 1 or 4.
- Therapy area
- Hepatology
- Line of therapy
- Any
- Evidence base
- Cost-minimisation
- Primary endpoint
- Cost-minimisation
- Economic model
- Cost-minimisation
- ICER note
- Minor submission; no economic evaluation conducted. Previously listed on a cost-minimisation basis (July 2016).
Similar precedents
Open on full dashboard →